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Background and Aim: Based on advances in the diagnosis, classification, and manage-
ment of diffuse large B-cell lymphoma (DLBCL), a number of new prognostic models have
been proposed. The aim of this study was to review and compare different prognostic models
of DLBCL based on the statistical methods used to evaluate the performance of each model,
as well as to analyze the possible limitations of the methods.
Methods and Results: A literature search identified 46 articles that proposed 55 different
prognostic models for DLBCL by combining different clinical, laboratory, and other para-
meters of prognostic significance. In addition, six studies used nomograms, which avoid risk
categorization, to create prognostic models. Only a minority of studies assessed discrimina-
tion and/or calibration to compare existing models built upon different statistical methods in
the process of development of a new prognostic model. All models based on nomograms
reported the c-index as a measure of discrimination. There was no uniform evaluation of the
performance in other prognostic models. We compared these models of DLBCL by calculat-
ing differences and ratios of 3-year overall survival probabilities between the high- and the
low-risk groups. We found that the highest and lowest ratio between low- and high-risk
groups was 6 and 1.31, respectively, while the difference between these groups was 18.9%
and 100%, respectively. However, these studies had limited duration of follow-up and the
number of patients ranged from 71 to 335.
Conclusion: There is no universal statistical instrument that could facilitate a comparison of
prognostic models in DLBCL. However, when developing a prognostic model, it is recom-
mended to report its discrimination and calibration in order to facilitate comparisons between
different models. Furthermore, prognostic models based on nomograms are becoming more
appealing owing to individualized disease-related risk estimations. However, they have not
been validated yet in other study populations.
Keywords: diffuse large B-cell lymphoma, discrimination, calibration, prognosis, models,
nomograms
Introduction
The most commonly used prognostic index for risk stratification of patients with
diffuse large B-cell lymphoma (DLBCL) is the International Prognostic Index
(IPI).1,2 Since the introduction of rituximab in DLBCL therapy, the discriminative
abilities of the IPI have been challenged in many studies.2–6 Predominantly, based on
the new insights into the pathobiology of disease, the predictive power of different
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biomarkers for prognosis has been extensively investigated
and this has led to numerous attempts at incorporating
clinical, biological, laboratory, immunohistochemical, and
genetic markers in prognostic scores.7–15 However, none of
the newly developed models has been as widely used as
the IPI.
Despite the standard treatment with chemoimmunother-
apy, approximately 30% of patients experience disease
relapse or are refractory to therapy.16 Therefore, the utiliza-
tion of selected group of patients’ characteristics through
a statistical model is important to identify high-risk patients
who could potentially benefit from more intensive immuno-
chemotherapy and/or molecular-targeted agents.17
Prognostic risk models, which are a mathematically precise
way to summarize properties of measurements and their
associations, are created to predict events.18 When develop-
ing a model, it is important to provide some evaluation of its
performance in comparison to an existing model.19 The
usefulness of a prognostic test in clinical practice depends
mainly on the ability of the test to stratify patients into
different risk groups and to provide accurate predictions
about their future outcome. However, when biomarkers are
included in statistical models for predicting a clinical out-
come, two problems can occur, namely “error in discrimina-
tion” and “error in calibration”.20 To achieve accurate risk
prediction, validation of the specific prediction model is
needed. For that task, various statistical methods have been
suggested in the literature.20–22
In our previous systematic review, we described the
studies that reported different prognostic models for newly
diagnosed DLBCL with a focus on clinical, laboratory,
molecular, and/or imaging parameters included in each
model. However, the analysis of statistical methods used
to compare the novel models in DLBCL with the pre-
viously reported models, to the best of our knowledge,
has never been performed. Therefore, this study aims to
investigate the statistical instruments that have been used
to develop, compare, and evaluate the performance of
prognostic models for DLBCL. Another aim is to analyze
possible limitations of each statistical method that can
restrict the wide usage of the derived model.
Materials and Methods
Search Strategy
Similarly to our previous research, this review was con-
ducted in accordance with the guidelines of the Preferred
Reporting Items for Systematic Reviews and Meta-
analysis.23 A comprehensive search was conducted in
PubMed and Embase to identify original publications
that proposed prognostic scores for newly diagnosed
DLBCL.24 Only studies in English published between
1993 and 15 July 2019 were considered.
The relevant Medical Subject Headings (MeSH) were
used where possible and the following search terms were
used in our analysis: lymphoma, large B-cell, diffuse/
DLBCL, index/indices, model, score, prognosis/prognos-
tic, outcome, survival, and comparison. The additional
eligible studies were retrieved through secondary
references.24 The search results were independently dou-
ble-screened by the research team (JJ, MM, BA) according
to inclusion/exclusion criteria at the abstract and the full-
text screening. All the studies included in the final list
were checked for data availability by BA and underwent
full statistical analysis, performed by ZB.
Selection Criteria and Data Extraction
This analysis included studies that developed a new risk
model for newly diagnosed DLBCL patients by combining
at least two parameters, of which one must be a clinical or
a laboratory parameter with or without imaging or
a molecular prognostic marker. The studies evaluated
overall survival (OS) using the Kaplan–Meier method
and/or expressed the outcome as the percentage of surviv-
ing patients. The exclusion criteria referred to all articles
that did not provide a new prognostic model (eg case
reports, commentaries, meeting reports, reviews), as well
as those that analyzed only one subtype of DLBCL, pro-
posed an index based exclusively on histopathological or
molecular data, and/or lacked sufficient data for estimating
OS. Moreover, we excluded studies that only tested scores
previously developed on patient populations other than
newly diagnosed DLBCL.24
After exclusion of the irrelevant studies based on the
titles and abstracts, the full texts of the selected articles
were analyzed. We also reviewed the full text of the
studies from which a decision could not be made on the
abstract alone. All studies included in the final list were
reviewed for their data accuracy.24 The data extracted from
each study were all of the following whenever reported:
author and publication year, index name, risk categories,
number of patients per group of new index and previously
reported index (eg IPI, revised IPI), model performance,
and OS expressed as the 3-year percentage of surviving
patients. If missing, the 3-year OS for newly created
models and previously reported models (used to compare
Jelicic et al Dovepress
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with the newly developed model) was estimated from the
survival curves using GetData Graph Digitizer 2.26.
Three-year OS was chosen because the majority of studies
report this endpoint.
For the studies that compared performance of a new
score and previously tested scores, the statistical methods
of comparison were recorded. Additional statistics included
c-index, Bayesian information criterion (BIC), concordance
probability estimate (CPE), Akaike’s information criterion
(AIC), Hosmer–Lemeshow goodness of fit, and receiver
operating characteristics (ROC) curves. The difference
between c-index was calculated in the studies that reported
the c-index. For each new score, the difference and propor-
tion between high- and low-risk groups were calculated. We
first extracted 3-year OS measures, then these values were
compared between high-risk and low-risk groups using
calculations of differences and proportions. Proportion was
assessed by dividing 3-year OS estimates in high-risk
patients by those in low-risk patients, while the difference
was calculated by subtraction of 3-year OS of the low-risk
group from the high-risk group. This value was expressed in
percentages. Furthermore, similar calculations were per-
formed if the studies reported 3-year OS survival for pre-
viously reported indices (eg IPI). If the 3-year OS was not
reached because of censored patients, or if the OS was 0%,
the proportion was labeled as not applicable (NA) for
mathematical reasons. The scores with the highest values
of the difference and proportion were regarded as those with
better differentiation between risk categories.
Results
The initial search strategy identified 5239 articles, but after
the inclusion/exclusion criteria were used, of 418 potentially
relevant articles, 46 studies were included in the final list.
Among these, seven additional articles were retrieved
through the references included in the eligible studies and
relevant reviews (Figure 1). Although the IPI was developed
based on a broad cohort of patients with aggressive lym-
phoma subtypes, this model was included in the current study
because it is widely used for prognostication in DLBCL.1,24
Furthermore, the search strategy identified six additional
studies that used nomograms to develop prognostic
models.25–30 Although these studies did not meet the inclu-
sion criteria regarding OS and risk stratification, they are
briefly discussed later owing to their individualized approach
for risk prediction. In total, 52 studies were analyzed.
In 46 studies, a total of 55 prognostic models were
proposed for DLBCL patients. From 1993 until 2019,
a significant increase in the number of proposed prognostic
models for DLBCL patients has been observed (Figure 2).
In all, 40 studies proposed one prognostic model, while
four studies proposed two models,10,31-33 one proposed
three,1 and one study proposed four prognostic models.11
In total, 26 prognostic models used a four-category risk
stratification with recognition of low-, low–intermediate-,
high–intermediate-, and high-risk groups (Tables 1–4).
Three-category risk stratification (low-, intermediate-,
and high-risk groups) was proposed in 20 studies. Two-
category risk stratification with high- and low-risk groups
was reported in six studies, while five-category risk strati-
fication was proposed in three studies.
Each of six studies that developed nomograms pro-
posed just one prognostic model based on the individual
risk prognostication. Additional data regarding each study
are provided in the supplementary table.
Statistical Analysis
Twelve of 46 studies analyzed populations with more than
400 patients (range 403–2031), while 32 studies included
fewer patients (range 45–391). Among studies based on
nomograms, three of six included more than 400 patients.
The majority of studies lacked the splitting of the
analyzed population into training and validation sets as
well as a comparison to previously proposed models.24
Seven studies of 46 used training and validation sets to
develop a prognostic index and to validate it.1,2,16,31,34-36
Among the studies using nomograms, three used both
internal and external validation,26–28 one used internal
validation only,25 and two did not assess the performance
through validation.29,30
Model performance was evaluated using different
methods, which are discussed in the following subsections.
C-Statistics
As a measure of discrimination, the area under the receiver
operating characteristics (ROC) curve for survival outcomes
(the c-index) was used in seven of 46 studies.7,16,32,34,37-39
Higher values of the c-index indicated better discrimination.
The value of the c-index for the novel prognostic models
ranged from 0.708 for the comorbidity National
Comprehensive Cancer Network-IPI (cNCCN-IPI) to 0.830
for the lipoprotein prognostic index (Lipo-PI). The c-index
was also calculated for the indices that were previously
reported, such as IPI (range 0.67–0.76), revised IPI
(c-index 0.642), and NCCN-IPI (range 0.6950.791). Two
studies pointed to the use of Harrell’s c-index/modified
Dovepress Jelicic et al
Clinical Epidemiology 2020:12 submit your manuscript | www.dovepress.com
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method as a discrimination method,16,32 while one reported
the use of the c-index according to Uno et al.22
Concordance Probability Estimate (CPE)
The discrimination of the newly developed prognostic
models and previously developed models was measured
by CPE along with its 95% confidence intervals (CI) in
four of 46 studies.2,3,10,40 A higher CPE indicated better
discrimination. The CPE value was 0.66 for E-IPI,3 0.781
for a new risk model,40 0.783 for modified NCCN-IPI,10
and 0.8 for NCCN-IPI. For the compared models, the
lowest CPE value was 0.59 for R-IPI,3 while the highest
was 0.76 for NCCN-IPI.40
Bayesian Information Criterion (BIC)
A global measure of fit, the BIC was assessed in two
studies, where lower values of BIC indicate a better fit.7,32
Akaike’s Information Criterion (AIC)
The performance of indices was compared by a measure of
global fit (AIC) in five studies, in which a lower value
indicated a better fit.2,3,9,31,40 The lowest AIC of 662.5 was
-initial database search (n=5239) 
-after removing obviously inappropriate studies that analyzed other Non-
Hodgkin lymphomas, therapy effect, trials, case reports, commentaries, 
etc (n=935) 
-non English studies (n=91)  
-exclusion based on title/abstract (n=268) 
-non human study (n=2) 
-validated indexes created on non-lymphoma populations 
(n=10) 
- evaluated only one type of DLBCL/localized 
disease/relapsed/refractory DLBCL (n=116) 
-reviews (n=30) 
-studies after manual screening and full text articles evaluated for future 
eligibility (n=418) 
-exclusion based on full-text screening (n=366) 
-lack of sufficient data for estimating OS (n=5) 
-nomogram based studies (n=6) for newly diagnosed 
DLBCL and (n=2) for relapsed/refractory DLBCL 
-studies included in final analysis (n=46) 
- nomogram based studies (n=6) 
In total: 52 
-studies retrieved through secondary references (n=7) 
Figure 1 Flowchart representing the selection process of including studies published between 1993 and July 2019.
Jelicic et al Dovepress
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observed in a new risk model,40 while the highest value
was 4566 in NCCN-IPI.2 Of the compared models, the
highest AIC value was observed in the IPI2 and the lowest
in NCCN-IPI.40
Hosmer–Lemeshow Goodness of Fit
One study used Hosmer–Lemeshow goodness of fit to
assess calibration, by comparing the proportions of
patients whose estimated risk shifted in the correct and
wrong directions on the basis of a χ2-test within reclas-
sified categories for each score separately.36
Relative Brier Score Reduction (RBSR)
One study reported RBSR, which represents a measure of
the overall model performance. The lower the Brier score
for a set of predictions, the better the predictions are
calibrated.34
Receiver Operating
Characteristics (ROC) Curves
In 11 of 46 studies, the cut-off of a continuously distributed
measurement for OS prediction was defined as the point at
which the sensitivity plus the specificityweremaximized in the
ROC curves.15,35,37,40-47 One study each used ROC curves to
select the best cut-off of beta-2 microglobulin (B2M),40
C-reactive protein (CRP),44 lymphocyte to monocyte ratio,44
platelet to lymphocyte ratio (PLR),45 tumor-infiltrating
T-lymphocyteproportion and ratio between CD4-positive and
CD8-positive T-lymphocytes,48 age,35 maximum standardized
uptake value,47 and ratio Deauville score.46 In two studies,
ROC was used to assess the albumin level,35,44 and in two
the absolute monocyte count and absolute lymphocyte
count.42,43 One study used X-tile software to calculate the
optimal cut-off value for the albumin to globulin ratio.41
Regarding the absolute monocyte count, absolute lym-
phocyte count, and platelet level, previously reported cut-
off points were used in five studies.9,33,49-51 However, the
majority of studies used institutional upper/lower limits of
normal (ULN/LLN) for the continuously distributed mea-
surements, including hemoglobin levels, platelet counts,52
absolute monocyte count, absolute neutrophil count, B2M,
LDH,37 B2M,36,45,53,54 and lipid levels.16
Three studies used other statistical techniques (eg per-
centile value, medians) for testing different cut-off points
of continuous measurements.8,33,55
Difference and Ratio in 3-Year Overall
Survival Between Risk Groups
Fifteen of 46 studies reported 3-year OS for novel prognostic
models, while OS was calculated from Kaplan–Meier curves
for the rest3,9,10,16,31,34,35,39,40,44,52,56-59 (Tables 1–3). Only
the minority of studies (six of 46) reported 3-year OS for
compared indices.9,10,31,39,44,52 Regarding 3-year OS of the
novel models, the highest ratio between the low- and high-
risk groups was 6,53 while the lowest was 1.31.41 These
studies included 71 and 335 patients, respectively. In six
articles the ratio in 3-year OS between low-risk and high-
risk groups was not applicable owing to the short follow-up
of high-risk patients or there being no surviving patients at 36
months.35,45,47,56,60,61 The difference in 3-year OS ranged
from 18.9%41 to 100%56 with335 and 105 patients, respec-
tively, being analyzed.
Regarding the IPI, the ratio between risk groups ranged
from 1.38 to 7.73, and the difference from 22.9% to 68.8%.
The lowest age-adjusted IPI (aaIPI) ratio score between the
low-risk and high-risk groups was 2.05 and the highest was
2.48, while the lowest difference was 42.0% and the highest
was 53.4%. Regarding NCCN-IPI, the ratio ranged from
1.75 to 3.70, and the difference from 40.9% to 72.9%.
Additional information regarding differences and the
ratios of other indices are provided in Tables 1–4.
Figure 3A and B shows the graphical presentation of the
ratio and difference, with preferable position close to the
upper right point, which indicates better model power. Both
Figure 2 Graph showing an increasing number of reported studies over the past
two decades.
Dovepress Jelicic et al
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parts of the figure allow the visual comparison of different
models owing to their position with the identical range on
the Xand Yaxes. The studies with a larger number of patients
had lower variability than the studies with a limited number
of patients (Figure 3A, B). Furthermore, it was observed that
the IPI in different studies tends to have a lower difference
and ratio (Figure 3B).
Prognostic Models Based on Nomograms
A total of six studies proposed prognostic models for
DLBCL patients based on calculated individual risk
using nomograms (Table 4).25–27,29,30 In all studies, the
predictive accuracy of the nomogram was evaluated using
discrimination and/or calibration. Three studies used split-
ting of the analyzed population into training and validation
sets.26–28 One study combined the machine learning
method, known as a stacking algorithm, with clinical
data obtained from nationwide lymphoma registries in
order to develop a stacking-based prognostic model,
which was superior to both IPI and NCCN-IPI.28
All nomogram-based studies reported the c-index25–30
and one study also applied integrated Brier score (IBS).28
Two studies reported the c-index for estimating progression-
free survival.25,30 The nomogram and other prognostic
indices were compared with the 2 log likelihood (2LL) and
the AIC in terms of goodness of fit in one study.29 Calibration
plots were reported in three nomogram studies26,27,29,while
one study applied Hosmer–Lemeshow goodness of fit to
assess calibration .25 New models were typically compared
with established indices such as IPI, NCCN-IPI, and R-IPI.
Discussion
Our review shows that a large number of new prognostic
models for patients with DLBCL have been proposed,
aiming at improving the discriminative power compared
to the IPI. However, general application of the majority of
these new prognostic models has been prevented because
of a lack of validation, limited number of analyzed
patients, and other statistical difficulties regarding model
development. The most commonly validated models used
for prognostication as well as for the comparison with
other novel models were IPI, R-IPI, and NCCN-IPI.24
Among these, NCCN-IPI had the highest performance
values, although the performance of models based on
nomograms was superior to the NCCN-IPI. However,
these models are relatively new and have not been vali-
dated in other study populations.
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The traditional splitting of data into the training and
validation data sets when developing a new model was
used in only 19% of studies. Using the training data set, it
is possible to construct an initial prediction model, the accu-
racy of which is then assessed using the validation set.
However, the usefulness of any model actually depends on
its accuracy, ie the ability of the model to correctly identify
each patient’s outcome.17 To report the discrimination (accu-
racy) value of the model, seven studies plus all studies based
on nomograms used the concordance (c) statistic, which is
conceptually similar to the ROC curve.17 The c-index scores
between 0.5 (no discrimination) and 1.0 (perfect
discrimination).20 The value of the c-index for novel prog-
nostic models ranged from 0.708, indicating a goodmodel, to
0.830, indicating a strong model. However, the c-index for
the widely applied indices such as IPI, R-IPI, and NCCN-IPI
had the lowest value of only approximately 0.6, which
defines low discrimination powers. In the analyzed studies
the c-index refers to time-to-event outcome (OS). In such
analyses, the c-index and its interpretation are less well
established than a binary outcome, since some patients had
not experienced an event at the time of analysis.17 There is no
consensus on how to handle time-to-event data, because this
requires exclusion of censored patients or using indirect
estimates of survival, based on the regression model, with
a tendency to give lower c-statistics than other methods.17,62
Another issue with the c-statistic is that it measures discri-
mination and not calibration, which is the agreement between
observed outcomes and predictions.17 The c-statistic is not
a good measure of the actual probability of events if only
a small number of patients experience the event of interest.17
In addition, four studies reported CPE in order to evaluate the
discriminatory power and the predictive accuracy of non-
linear statistical models.2,3,10,40 An early estimate of the
concordance probability, which was the predominant discri-
mination statistic adapted for survival analysis, was Harrell’s
c-index, used in three studies.16,25,32,63 However, Harrell’s
c-index was influenced by the rate of patient accrual and the
length of the study. To avoid this limitation, Uno et al intro-
duced inverse probability censoring weights to the c-index.
This method was used in one study.22,33,39
In six studies, the performance of indices was compared
using the AIC.2,3,9,29,40,64 To compare the quality of a set of
statistical models (to perform model comparisons) with each
other, two studies used another criterion for model selection –
the BIC, which measures the trade-off between model fit and
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complexity of the model.7,18,32 Both BIC and AIC balance
the level of fit (based on the log-likelihood, a basic estimate
of fit) with model complexity. Furthermore, the formula for
the BIC is similar to the formula for the AIC, but with
a different penalty for the number of parameters.18 Lower
AIC and BIC values are preferred, and indicate a more
explanatory and informative model.64 The AIC is the com-
monly used model selection tool for choosing between alter-
native models and has a preference for more complexmodels
compared to the BIC, owing to its ability to eliminate unne-
cessarily complicated models, which contain too many para-
meters for accurate estimation on a given data set.64
However, the AIC takes into account each model and ranks
them from the best to worst, then it chooses between the
models based on the goodness of fit using the lowest number
of variables that explains the outcome best. This means that if
all models are poor, it will choose the best of these, because
quality is not taken into account.65 Furthermore, when the
sample size is small, there is a high probability that the AIC
will select models that have too many parameters, leading to
overfitting. To address such potential overfitting, alternative
versions of the AIC have been proposed to make it easier to
compare models estimated on different data sets of varying
sizes.66
Two studies used the Hosmer–Lemeshow test goodness
of fit to assess calibration.25,36,67 Models are well cali-
brated if expected and observed event rates in subgroups
of risk models are similar. The main limitations of this test
are that it is based on an arbitrary grouping of observa-
tions, it has poor power in small data sets, and the result is
expressed only in a p-value.68 In addition, three models
used a calibration plot, described as a graphical illustration
of the Hosmer–Lemeshow test, which is another method to
assess calibration in which the observed event status is
plotted against the predicted risk estimates. The plot is
often supplied with a calibration curve to help to diagnose
a lack of fit, and will lie on the 45-degree line in a well-
calibrated model.68,69 Some authors have suggested the
use of the calibration slope, which, in addition to the
p-value, provides a confidence interval and a measure of
size of effect, since the estimated slope is obtained from
the regression model and does not require the patients to
be grouped. Therefore, the calibration slope does not suf-
fer from the limitations of the Hosmer–Lemeshow test.68
To determine the optimal cut-off point for contin-
uous measurements for predicting OS, 11 of 46 studies
used the ROC curve, which maximizes the likelihood
ratio.15,35,37,40–47 The ROC curve analysis has earned
a place in biomedical studies when interpreting the
results of diagnostic accuracy of a continuous marker.
The performance of a marker is evaluated by the area
under the ROC curve (AUC), an indicator of overall
“accuracy”, in which a higher AUC value indicates
a better performance. However, there is variation in
the sensitivity and specificity from point to point
along the ROC curve and therefore it is important to
consider the aims of diagnostic tests with respect to the
significance and costs of a false-positive or negative
interpretation.70 Regarding the cut-off points of contin-
uous variables used in prognostic models in DLBCL, it
is obvious that different thresholds based on ROC
results were incorporated in the models, where an addi-
tional five studies used cut-off points that had already
been reported.9,33,49–51 However, in ROC, one’s choice
of the value based on specificity and sensitivity can
largely depend on the data set, meaning that the opti-
mal cut-off value in one population might not be the
optimal value in another.
Because of the lack of comparisons between prognostic
models and the use of a variety of statistical methods formodel
comparison, it was not possible to make a universal compar-
ison. Therefore, we have chosen to compare models by using
very simple tools: the difference and proportion between
scores among low-risk and high-risk groups. The bigger the
observed value between the low- and high-risk groups, the
better the model’s power. However, the number of patients in
the high-risk group has a major impact on the results. Hence, it
is not surprising that the highest ratio was observed in a study
including just 73 patients, while the highest difference was
observed in a study that analyzed 337 patients. However, these
tools have pointed to the rather limited power of the IPI, as
well as the lower prognostic value of models developed in
a limited number of patients. Although these are simple meth-
ods of comparison, they can give a false impression of super-
iority of one model, possibly due to a limited number of
patients in high-risk groups or relatively short follow-up.
Thus, they should be used as an addition to other performance
measures and not as the primary method of comparison owing
to these limitations. The studies that used nomograms pre-
sented a visual representation of a statistically predictive
model that estimates the probability of a clinical event by
calculating the cumulative effect of weighted independent
variables.71 Although these models cannot be compared by
the ratio or difference because they do not use risk categories,
they provide the discrimination and/or calibration to compare
different prognostic models. Irrespective of the fact that that
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these complex models did not entirely fulfill our inclusion
criteria, their recognition indicates the current trend towards
more individualized prognostication. This is mainly due to the
fact that grouping of patients into risk categories results in an
ineffective use of the data and tends to reduce the predictive
accuracy of a prognostic model. In addition, the complexity of
nomograms can be offset by using electronic versions.72 Still,
there are no guidelines regarding which value could be used in
decision making when nomograms are used for prognostica-
tion. However, it would advance clinical application if future
studies evaluated nomograms in the risk-adapted therapeutic
strategies.26 Nevertheless, due to other limitations of nomo-
grams, the focus of future studies, besides developing new
models, should be validation of the existing prognostic
models.73
In addition, one study developed a prognostic model by
combining data from a clinical database withmachine learning
techniques.28 The stacking algorithm, used in the study, is
a way of ensembling multiple regression models to obtain
survival curves, eliminating the need for the specification of
one prognostic modeling approach.74 Although the machine
learning technique is not a new concept, it is gaining more
attention in the classification, prognostication, and genetic
analysis of DLBCL.28,75,76 It is evident that the clinical and
genetic heterogeneity of DLBCL, as well as overlapping of
DLBCL subgroup classifications, represent significant chal-
lenges for accurate outcomes prediction.74 To provide
a prediction of clinically relevant outcomes for patients with
DLBCL, future studies will likely have to combine different
factors (clinical, sociodemographic, tumor microenvironment,
genetic, etc), possibly with the aid of the machine learning and
high-dimensional data analysis or other statistical methods in
order to develop comprehensive, multilevel prognostic models
that should be easily applicable in clinical care.74
Conclusion
Although an increasing number of prognostic models for
DLBCL has emerged in the past two decades, there is no
universally accepted statistical method of reporting prognos-
tic models in DLBCL. When reporting a new prognostic
model, we would recommend assessing the discrimination
and calibration of the prognostic model. Other measures of
its performance may be used when adding a novel predictor
to an established model.19 In addition, comparisons of dif-
ferent available prognostic models based on the same popu-
lation should be provided. This is needed in order to avoid the
vagueness that currently exists in the literature, owing to an
inability to compare current prognostic models in DLBCL.
Furthermore, to adapt models to a more individualized
approach, an increasing number of models based on nomo-
grams has been published. These models generally report the
discrimination and calibration in order to compare the novel
model with previous models, and tend to have higher pre-
dictive accuracy by avoiding potential loss of information
due to the omission of risk categorization. However, future
prognostication studies that integrate advances in statistics
with growing knowledge on the diagnostics, pathology, and
therapy of DLBCL are necessary.
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